Literature DB >> 100622

Valproic acid (Depakene). A new anticonvulsant agent.

J R Lewis.   

Abstract

Valproic acid, a new anticonvulsant, is most effective in absence seizures (simple and complex), but it has produced improvement in tonicclonic seizures, mixed absence with tonic-clonic seizures, and myoclonic epilepsy. It is useful alone or as an adjunct to other anticonvulsants and may allow the dosage of the latter to be reduced. Some patients who are refractory to other anticonvulsants may respond to valproic acid. Adverse reactions occur in about 20% of patients. Gastrointestinal disturbances and drowsiness (usually noted when valproic acid is given with other anticonvulsants) are the most common reactions; hair loss is observed less frequently. Untoward effects are usually transient and do not require discontinuation of use of the drug.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 100622

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  4 in total

1.  Sodium valproate and thrombocytopenia.

Authors:  L M Hoffman
Journal:  Can Med Assoc J       Date:  1982-02-15       Impact factor: 8.262

Review 2.  Therapeutic Basis of Generic Substitution of Antiseizure Medications.

Authors:  Sarah Elmer; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2022-03-03       Impact factor: 4.402

3.  Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition.

Authors:  Dahea You; Jason R Richardson; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2020-03-19       Impact factor: 3.922

4.  Assessment of need for hemostatic evaluation in patients taking valproic acid: A retrospective cross-sectional study.

Authors:  Demi S Post; Arian van der Veer; Olaf E M G Schijns; Sylvia Klinkenberg; Kim Rijkers; G Louis Wagner; Vivianne H J M van Kranen-Mastenbroek; Paul C P H Willems; Paul W M Verhezen; Erik A M Beckers; Floor C J I Heubel-Moenen; Yvonne M C Henskens
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.